Inventera Inc. Applies for Pre-NDA Meeting with the Ministry of Food and Drug Safety for MRI Contrast Agent ‘Asolux’
Initiates Preliminary Review of Regulatory Submissions Following Acquisition of Phase 3 Clinical Trial CSR
Clinical Trial Involving 85 Patients Meets All Three Primary Endpoints
Iron-Based Nano-MRI Contrast Agent… Pushing for Domestic Commercialization and Overseas Expansion
[Edaily Reporter KIM SAE-MI ] #Inventera Inc. has begun preliminary preparations to apply for domestic marketing authorization for its new magnetic resonance imaging (MRI) contrast agent drug candidate, “Asorux Injection” (development code INV-002).
Inventera Inc. CI (Photo: Inventera Inc.) Inventera Inc. announced on the 17th that it has requested a pre-NDA (New Drug Application) consultation meeting with the Ministry of Food and Drug Safety regarding “Artholux Injection,” a nano-MRI contrast agent for MR arthrography.
Artholux Injection is a candidate drug previously known as “NEMO-103 Injection,” and this marks the first time the product name has been disclosed. The name “Artholux Injection” combines the English term “arthrography,” which refers to joint imaging, with the Latin word “lux,” meaning light.
A Pre-NDA meeting is a procedure in which a company discusses submission materials—including nonclinical, clinical, and quality data—and key issues with regulatory authorities prior to filing a new drug application. Following the acquisition of the final Clinical Study Report (CSR) for its Phase 3 clinical trial last September, Inventera Inc. plans to use this meeting to review the materials required for the approval application.
Previously, the Ministry of Food and Drug Safety (MFDS) pushed forward with a reform of its approval and review system last month, shortening the total duration of the new drug approval and review process—including the period for supplementary data submission—to 240 days. Inventera Inc. has previously discussed the adequacy of its non-clinical and clinical data through MFDS pre-reviews in September of last year, as well as in January and June of this year.
Asorlux is a new T1 nano-MRI contrast agent candidate that utilizes iron instead of gadolinium, a rare earth metal used in existing MRI contrast agents. It is being developed specifically for MR arthrography to diagnose musculoskeletal disorders and is designed to be administered directly into the joint cavity without the need for separate dilution or preparation.
Inventera Inc. conducted a Phase 3 clinical trial involving 85 patients with confirmed or suspected shoulder joint disorders at eight leading general hospitals in Korea, including Seoul National University Bundang Hospital. The trial began with the first patient dosing in September of last year, completed follow-up of the last subject in April of this year, and received the final CSR in September.
According to the company, an independent central review comparing non-contrast MRI images with MR arthrography images using Asorux Injection from the same patients confirmed statistically significant improvements in all three primary endpoints—joint expansion, contrast ratio, and clarity (p < 0.0001 for each).
Significant improvements were also observed in secondary image quality metrics, such as the contrast-to-noise ratio (CNR) and lesion-to-background ratio (LBR) (p < 0.0001 for each). The company explained that it also identified cases where lesions—such as rotator cuff tears, glenoid labral tears, and articular cartilage tears—that were not detected on non-contrast MRI were additionally discovered.
Inventera Inc. is currently focusing on the fact that there are cases in South Korea where intravenous gadolinium contrast agents are being diluted and used off-label for MR arthrography. The company expects that once Solux Co., Ltd. receives approval, it will reduce the burden of on-site preparation as a contrast agent specifically designed for direct injection into the joint cavity.
Inventera Inc. also plans to expand into overseas markets after obtaining domestic marketing authorization. According to data from The Insight Partners, a global market research firm cited by the company, the global market for MR arthrography is estimated to be approximately 1.65 trillion won this year and is projected to exceed 2.2 trillion won by 2030.
An Inventera Inc. official stated, “Based on the results obtained in the Phase 3 clinical trial, we will proceed with the marketing authorization process without delay and prepare to launch the product in the domestic market promptly after obtaining approval.” The official added, “Following the domestic launch, we plan to enter the global market by sequentially pursuing marketing authorization applications overseas.”
The following is a summary of the report series titled “Assessing the Impact of a U.S.-Iran War by Industry,” which took third place in the Best Report category at the 37th SRE Awards. On February 28,…
Daesang ( Daesang(001680)) is donating Cheongjeonwon food sets worth 100 million won to help vulnerable residents in Jongno-gu, Seoul, get through the winter.
Daesang’s Head of ESG Management, Kim …
Lee Won-jik, President of HLB Pep. (Photo courtesy of HLB Pep)
HLB Pep ( ANYGEN CO., LTD.(196300)), a company specializing in peptide active pharmaceutical ingredients (APIs), has appointed Lee Wo…